Leadership & Pay ·
Adial changes name to Azora Therapeutics and appoints new CEO Matt Davidson
ADILAzora Therapeutics, Inc. (DE)
Stockholders approved the conversion of Series A preferred stock into common shares and authorized a change of corporate name from Adial Pharmaceuticals, Inc. to Azora Therapeutics, Inc., effective October 29, 2026. Trading on Nasdaq will resume under the new ticker symbol AZR. The Board appointed Matthew Davidson as President and CEO, succeeding Cary Claiborne, while Celia Economides was named CFO and Julie Saiki became Chief Strategy Officer. The company is advancing its lead asset AT177, an oral AhR agonist for ulcerative colitis, with Phase 1 trials expected in the first half of 2027. Azora Therapeutics operates as a biopharmaceutical company developing treatments for serious inflammatory diseases.